Gestational Trophoblastic Neoplasia
16
8
9
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 65/100
6.3%
1 terminated out of 16 trials
0.0%
-86.5% vs benchmark
19%
3 trials in Phase 3/4
0%
1 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Clinical Trials (16)
Study of Different Therapeutic Strategies in Hydatidiform Mole With Lung Nodule
Camrelizumab Plus Apatinib in Patients With High-risk Gestational Trophoblastic Neoplasia
Uterine Artery Doppler Flow Velocimetry Parameters for Predicting the Occurrence of Persistent Gestational Trophoblastic Neoplasia After Evacuation of Complete Hydatiform Mole
Biweekly Actinomycin-D Treatment or Multi-day Methotrexate Protocol in Low-risk Gestational Trophoblastic Neoplasia
The Psychological Impact of GTN on Women Who Have Completed Chemotherapy Treatment
Toripalimab Plus Actinomycin-D as Fist-Line Treatment for GTN With FIGO Score 5-6
Toripalimab Plus Actinomycin-D As Fist-Line Treatment for GTN with FIGO Score 7
Clinical Specialty Queue For Gestational Trophoblastic Neoplasia
A Feasibility Window Study of Pembrolizumab Prior to Second Evacuation for Post-molar Gestational Trophoblastic Neoplasia
Dostarlimab in Chemoresistant Gestational Trophoblastic Neoplasia
Study of Hysteroscopic Repeat Curettage as the First-line Treatment in Low-risk Postmolar Gestational Trophoblastic Neoplasia
Study of PD-1 Antibody and Bevacizumab in the Treatment of High-risk GTN After Combined Chemotherapy
Second Uterine Evacuation for Low-risk Gestational Trophoblastic Neoplasia
Phase 2 Trial for Chemo-Resistant Gestational Trophoblastic Neoplasias With Pembrolizumab (CR-GTP)
Methotrexate Single-dose Treatment and Methotrexate/Actinomycin-D Single-dose Treatment in Low-Risk Gestational Trophoblastic Neoplasia
Study of TRC105 and Bevacizumab in Patients With Refractory Gestational Trophoblastic Neoplasia (GTN)